title: Hit me with your best shot: dolutegravir - a space in the next WHO guidelines?
authors.affiliation: aMédecins Sans Frontières Access Campaign, Geneva, Switzerland bThe Desmond Tutu HIV Centre, University of Cape Town, Republic of South Africa cHIV Unit, Department of Internal Medicine, Geneva University Hospital, Geneva, Switzerland.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Cohn
authors.forename: Linda-Gail
authors.initials: LG
authors.lastname: Bekker
authors.forename: Helen
authors.initials: H
authors.lastname: Bygrave
authors.forename: Alexandra
authors.initials: A
authors.lastname: Calmy
mesh_terms: D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage*; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage*; D006801:Humans; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D016896:Treatment Outcome; D000099226:Dolutegravir
chemical_list: D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099226:Dolutegravir